Aug 8, 2024
WaveData MD, Charles Joynson shares his analysis….. It seems relatively obvious to say that if there is a serious shortage there probably won’t be much stock of any form around, generic, brand, parallel import or short dated. This probably means that any short...
Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 27, 2024
Finally, it really does feel like Summer. Looking out of the window at WaveData HQ the sky is blue and the sun is shining. It will be ice creams all round at lunch time today! It’s not just the temperature that’s hotting up….. Dave Wallace at The Generics...
Jun 27, 2024
Whilst researching for the June edition of WaveData’s Bulletin, Editor Jackie Moss flagged up Olanzapine Tabs 10mg 28 as one to watch. After a reasonably long period of stability, with the average price not exceeding £0.80 since April 2022, we have seen a month on...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
Jun 6, 2024
What happens when the department of health (DHSC) agree an increase in the reimbursement price of a brand (VPAS or VPAG)? How does this affect parallel imports? Charles Joynson, WaveData MD, looked at four products which had both had increases in reimbursement and...
